GenVec Inc. HIV Vaccine Program To Receive Additional Funding

GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) announced today that it will receive up to $3.56 million in new funding to support the development and manufacture of novel adenovector-based HIV vaccines under its multi-year collaboration with the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. These additional funds increase the total value of GenVec’s subcontract for this program to $53 million over the life of the agreement, which extends through the end of fiscal year 2008. The subcontract was issued and is managed by Science Applications International Corporation-Frederick, Inc (SAIC-Frederick).
MORE ON THIS TOPIC